Meeting
2014 ASCO Annual Meeting
Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma.
Authors
Bart Neyns
Universitair Ziekenhuis Brussels, Brussels, Belgium
Bart Neyns , Johnny Duerinck , Stephanie Du Four , Frank Bouttens , Vincent Verschaeve , Hendrik Everaert , An Van Binst
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01562197
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2018)
DOI
10.1200/jco.2014.32.15_suppl.2018
Abstract #
2018
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
First Author: Yazmin Odia
Poster
2019 ASCO Annual Meeting
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
First Author: Bart Neyns
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick
Poster
2016 ASCO Annual Meeting
Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
First Author: Johnny Duerinck